TARGAN (formerly Applied LifeSciences & Systems (ALSS)) has secured $35 million in a Series C equity funding round co-led by Mountain Group Partners and NovaQuest Capital Management.
Existing investors Merck Animal Health and Oval Park Capital also participated in the round.
TARGAN integrates its proprietary technologies consisting of high-speed imaging, feature recognition, artificial intelligence, robotics, and microfluidics in a system currently developed for the commercial poultry industry.
The Series C investment will allow TARGAN to accelerate the commercialisation of its automated and individualised poultry vaccination and gender identification systems.
